Pharmaceuticals - Worldwide

  • Worldwide
  • The projected revenue in the Pharmaceuticals market is estimated to reach €1,072.00bn in 2024.
  • Among the various markets, Oncology Drugs is expected to be the largest, with a projected market volume of €198.50bn in 2024.
  • Looking ahead, the revenue in this sector is anticipated to exhibit an annual growth rate (CAGR 2024-2028) of 6.40%, resulting in a market volume of €1,374.00bn by 2028.
  • When comparing globally, it is noteworthy that United States is expected to generate the highest revenue of €590.60bn in 2024.
  • The Pharmaceuticals market encompasses various countries worldwide.
  • Due to its advanced healthcare infrastructure and strong R&D capabilities, the United States remains at the forefront of pharmaceutical innovation worldwide.

Key regions: United States, China, Germany, Japan, Europe

 
Mercado
 
Región
 
Comparación de regiones
 
Moneda
 

Analyst Opinion

The Pharmaceuticals market has been growing steadily in recent years, which is mainly driven by innovative drugs and an increasing demand for drugs and treatments worldwide.

Customer preferences:
Customers in the Pharmaceuticals market are increasingly looking for personalized and targeted treatments, with a focus on preventative healthcare. This has led to a rise in demand for precision medicines, which are tailored to specific genetic profiles and offer more effective treatments with fewer side effects. Compared to the revenue generated by prescription drugs, OTC pharmaceuticals only play a minor role. The market for prescription drugs, for its part, is dominated by original products. Nonetheless, there is a growing demand for over-the-counter (OTC) drugs, which are easily accessible and can be purchased without a prescription.

Trends in the market:
The Pharmaceuticals market is characterized by disruptions due to innovative drugs and expiring patents. The market has been dominated by large pharmaceutical companies, which have been investing heavily in research and development to bring new drugs to market. However, there has been a rise in the number of generic drug manufacturers, who are able to offer cheaper alternatives to branded drugs. This has led to increased competition and a shift towards more affordable healthcare. In Europe, there has been a focus on cost containment, with governments and healthcare providers looking for ways to reduce the cost of healthcare. This has accelerated the use of biosimilars, which are cheaper alternatives to biologic drugs. In Asia, the Pharmaceuticals market has been growing rapidly, driven by an increasing demand for healthcare services and a rise in disposable income. There has been a focus on innovation, with a rise in the number of biotech startups and a growing interest in precision medicine. Furthermore, there has been a shift towards online pharmacies and telemedicine, which offer greater convenience and accessibility for patients.

Local special circumstances:
In general, the Pharmaceuticals market is highly regulated. It is usually characterized by strict approval processes and strong patent legislation. Regulations, the availability and approval of drugs, and the period of exclusivity vary greatly from country to country. In Africa, the Pharmaceuticals market has been hindered by a lack of infrastructure and regulatory frameworks, which has made it difficult for pharmaceutical companies to operate in the region. However, there has been a growing interest in the market, with a rise in investment and partnerships with local companies. Additionally, there has been a focus on improving access to healthcare, with a rise in the number of mobile health clinics and community health workers.

Underlying macroeconomic factors:
The Pharmaceuticals market is heavily influenced by macroeconomic factors, such as government policies, healthcare spending, and demographic trends. In developed countries, there has been a rise in healthcare spending, driven by an aging population and a rise in chronic diseases. In developing countries, there has been a focus on improving access to healthcare, with a rise in government funding and investment from international organizations. Additionally, there has been a growing trend towards digitalization and automation, which has led to increased efficiency and cost savings in the pharmaceutical supply chain.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Visión general

  • Revenue
  • Analyst Opinion
  • Key Players
  • Research & development
  • Global Comparison
  • Methodology
  • Key Market Indicators
Espere, por favor

Contacto

¿Alguna duda? Estaremos encantados de atenderte.
Statista Locations
Contacto Nerea Marcos
Nerea Marcos
Client Success Manager

Lu - vi, 9:30 - 17:00 h (CET)

Contacto Meredith Alda
Meredith Alda
Sales Manager– Contacto (Estados Unidos)

Lu - vi, 9:00 - 18:00 h (EST)

Contacto Yolanda Mega
Yolanda Mega
Operations Manager– Contacto (Asia)

Lu - vi, 9:00 - 17:00 h (SGT)

Contacto Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contacto (Asia)

Lu - vi, 10:00 - 18:00 h (JST)

Contacto Lodovica Biagi
Lodovica Biagi
Director of Operations– Contacto (Europa)

Lu - vi, 9:30 - 17:00 h (GMT)

Contacto Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contacto (América Latina)

Lu - vi, 9:00am-6:00pm (EST)